Shanghai Haisishengnuo Pharmaceutical Technology

Shanghai Haisishengnuo Pharmaceutical Technology is a China-based innovative drug R&D company and a subsidiary within the Haisco Pharmaceutical Group. The company appears focused on discovery and early clinical development of small-molecule therapeutics, with disclosed programs spanning dermatology, oncology, respiratory disease, and metabolic disease. Public disclosures link the company to HSK44459, which has advanced into Phase 2 for atopic dermatitis and has additional development activity in psoriasis and topical formulations, as well as earlier-stage assets including HSK50042, HSK55879, and HSK39297. Corporate registry information indicates it was established in Shanghai in late 2022 and remains active. Overall, it functions as an innovation-focused R&D vehicle inside Haisco's broader pharmaceutical organization rather than as an independently listed company.